Applications of Tert-Butyl(4S)-1-Methyl-2-Oxoimidazolidine-4-Carboxylate in Industrial Manufacturing

As a dedicated manufacturer, we supply Tert-Butyl(4S)-1-Methyl-2-Oxoimidazolidine-4-Carboxylate to industry leaders for targeted synthesis in regulated sectors. This compound supports strict formulation protocols and advanced process control, contributing to traceable downstream value chains. Below are verified industrial use cases where this intermediate provides proven value, embedded in real production workflows.

1. Pharmaceutical API Intermediate Synthesis

Major pharmaceutical manufacturers utilize this material as an advanced intermediate during the asymmetric synthesis of protected imidazolidinone derivatives. The compound enters multi-step active pharmaceutical ingredient (API) routes, especially for β-lactam antibiotics and peptidomimetic drugs. Operators adhere to precise reaction monitoring under high-purity demands, with integrated in-process controls ensuring batch-to-batch consistency and full traceability for clinical development and commercial scale-up.

Industry compliance standards

• Current Good Manufacturing Practices (cGMP, ICH Q7)
• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• FDA 21 CFR Parts 210/211

Typical usage ratio

• Used at stoichiometric ratios specific to target molecule, generally 1.05–1.15 equivalents in protected intermediate formation
• Exact dose depends on target yield, step efficiency, and impurity control

Downstream process integration

• Introduced during protected condensation or cyclization steps after initial substrate derivatization
• Applied under inert atmosphere with temperature control, followed by deprotection or coupling reactions

Final product types

• Pharmaceutical active ingredients for anti-infective and anti-inflammatory therapies
• Clinical-stage API for oncology and peptide-based drug development

2. Peptide Synthesis and Protected Amino Acid Building Blocks

Peptide and oligopeptide producers incorporate this raw material as a chiral protected building block to construct custom peptide chains. The tert-butyl carbamate function enables efficient solid-phase peptide synthesis (SPPS) and solution-phase coupling. Its reactivity minimizes side reactions, supporting scalable and reproducible assembly of high-purity peptidic pharmaceuticals, veterinary actives, and diagnostic probes. Analytical release involves batch-specific NMR and mass spectrometry to confirm identity and purity.

Industry compliance standards

• International Conference on Harmonisation Q11 Process Validation
• GMP for Active Pharmaceutical Ingredients (EU GMP Vol. 4 Part II)
• USP General Chapters for amino acid derivatives

Typical usage ratio

• 0.9–1.2 equivalents relative to coupling partners during SPPS or solution synthesis
• Adjusted for resin loading or solution concentration based on target peptide length

Downstream process integration

• Fed into initial amino acid protection or following resin swelling (for SPPS)
• Enables selective deprotection for controlled chain elongation

Final product types

• Therapeutic peptides for metabolic or autoimmune disorders
• Tumor-targeted peptide-drug conjugates (PDCs)
• In vitro diagnostic reagents

3. Fine Chemical Synthesis for Agrochemical Intermediates

Agrochemical manufacturers apply this compound during synthesis of chiral intermediates for crop protection agents and specialty fertilizers. The compound's stereochemical integrity is critical for downstream activity in fungicides and herbicide actives. Process QC validates that input material meets strict enantiomeric purity and residual solvent thresholds. Its incorporation ensures robust yield in downstream alkylation and cyclization reactions, maximizing throughput and minimizing by-product formation.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals
• EU REACH Regulation (EC) No 1907/2006
• ISO 9001:2015 Quality Management System

Typical usage ratio

• 0.8–1.1 equivalents dependent on crop protection active formulation requirements
• Ratio selected for enantiopure product specification and minimized waste

Downstream process integration

• Integrated during intermediate building stage prior to functional group transformation
• Batch addition at controlled pH and solvent polarity for optimal conversion

Final product types

• Chiral intermediates for triazole fungicides
• Active ingredients for selective herbicides
• Seed treatment additives

4. Chiral Auxiliaries in Chemical Process Research

Process innovation teams in chemical R&D facilities use this chiral compound as a stereoselective auxiliary for exploring asymmetric catalysis and enantioselective transformations. The material serves as a test substrate in screening new ligands, optimizing enantiomeric excess, and scaling up promising synthetic methodologies for patent applications. Analytical data from high-performance liquid chromatography establishes reproducible chiral induction and conformational stability.

Industry compliance standards

• ISO 17025 Testing and Calibration Laboratories
• Internal company-specific SOPs governing laboratory reagent certification

Typical usage ratio

• Investigative runs: 1.0 equivalent as substrate or auxiliary
• Optimization batches: 5–10 mmol scale for process parameter definition

Downstream process integration

• Added as induction agent in early-stage asymmetric synthesis trials
• Used to benchmark process reproducibility, followed by removal or recovery

Final product types

• Process research samples for patent chemistry
• Characterized intermediates for future manufacturing scale-up

5. Contract Custom Synthesis for Biotech Pilot Projects

We manufacture this intermediate for leading biotech firms involved in custom molecule design and preclinical evaluation. Downstream users specify absolute configuration, analytical reports, and impurity profiles to align with project milestones and regulatory submissions. In custom projects, the compound supports pilot-scale synthesis and modification of small molecule libraries intended for early pharmacological screening, with rigorous chain-of-custody maintained throughout the supply and documentation process.

Industry compliance standards

• ISO 13485:2016 (for diagnostic end products)
• Customer-specified specification sheets and CMC documentation
• GLP (Good Laboratory Practice) for non-clinical studies

Typical usage ratio

• Custom batches: 0.5–5.0 mol depending on library size and target compound design
• Ratio defined in collaboration with the contract partner per unique protocol

Downstream process integration

• Employed in parallel synthesis workflows after route scouting
• Used for derivatization, fragment coupling, or scaffold assembly phases

Final product types

• Small molecule clinical candidates for preclinical testing
• Diagnostic molecular probes
• Digital library reference standards